CLGN CollPlant Biotechnologies Ltd Forecast, Technical & Fundamental Analysis
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics... Show more
CLGN is expected to report earnings to rise 16.57% to -24 cents per share on August 20
Q2'26
Est.
$-0.24
Q1'26
Beat
by $0.03
Q4'25
Missed
by $0.13
Q3'25
Missed
by $0.41
Q2'25
Beat
by $0.37
The last earnings report on May 29 showed earnings per share of -20 cents, beating the estimate of -23 cents. With 44.45K shares outstanding, the current market capitalization sits at 5.34M.
A.I.dvisor tells us that CLGN and CLLS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLGN and CLLS's prices will move in lockstep.
CLGN's Stochastic Oscillator sits in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLGN advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .
CLGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLGN as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CLGN turned negative on June 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CLGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.092) is normal, around the industry mean (19.567). P/E Ratio (0.000) is within average values for comparable stocks, (35.932). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.687). CLGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (12.151) is also within normal values, averaging (355.865).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
